We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
COVID -19: On the threshold of the fifth year. The situation in Spain.
- Authors
Rodríguez-Artalejo, Fernando; Ruiz-Galiana, Julián; Cantón, Rafael; De Lucas Ramos, Pilar; García-Botella, Alejandra; García-Lledó, Alberto; Hernández-Sampelayo, Teresa; Gómez-Pavón, Javier; González del Castillo, Juan; Cruz Martín-Delgado, Mari; Martín Sánchez, Francisco Javier; Martínez-Sellés, Manuel; Molero García, José María; Moreno Guillén, Santiago; García de Viedma, Darío; Bouza, Emilio
- Abstract
Despite having emerged from pandemic status, the incidence of COVID-19 episodes has recently increased in Spain, including pediatric cases and admissions to Intensive Care Units. Several recombinant variants are circulating among us, particularly XBB arising from two Omicron BA.2 sublineages with mutations in the genes encoding the spicule proteins that could increase binding to the ACE2 receptor and be more prone to immune escape. Faced with these, 3 pharmaceutical companies have developed vaccines adapted to the XBB.1.5 sublineage that are already available for administration in our setting with risks that should not be different from those of previous mRNA vaccines and with clearly favorable benefit/risk ratios. They should be applied to patients with potential for poor COVID-19 evolution and to collectives that have a particular relationship of proximity with them. Their application should be understood not only from a perspective of individual convenience but also from that of collective responsibility. The most convenient seems to be a simultaneous immunization of COVID-19 and influenza in our environment. In the therapeutic aspect, there is little to expect right now from antisera, but the already known antiviral drugs are still available and indicated, although their efficacy will have to be reevaluated due to their impact on populations that are mostly immunized and with a better prognosis than in the past. In our opinion, it is necessary to continue to make a reasonable and timely use of masks and other non-pharmacological means of protection.
- Subjects
SPAIN; COVID-19 pandemic; INTENSIVE care units; ANGIOTENSIN converting enzyme; GENETIC mutation
- Publication
Revista Española de Quimioterapia, 2024, Vol 37, Issue 1, p17
- ISSN
0214-3429
- Publication type
Article
- DOI
10.37201/req/123.2023